Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Subscribe To Our Newsletter & Stay Updated
